Humaniche is an ETH Zürich spin-off in formation, developing a family of off-the-shelf and disease-specific human bone marrow niche proxy kits and in vitro systems that provide structured insights into efficacy and hematopoietic toxicity at the stage immediately prior to first-in-human trials, where development risk and capital exposure are highest.
Until now, it has raised CHF 588K in non-dilutive funding.
By introducing functional human bone marrow biology into late preclinical decision-making, Humaniche reduces costly late-stage clinical failures and supports the pharmaceutical industry’s transition toward validated New Approach Methodologies (NAMs).
By developing human-relevant, scalable, and reproducible bone marrow disease model tools, Humanishe aims to enable safer, more effective advanced therapies to efficiently reach blood cancer patients.
ETH Zurich ScopeM offers access to advanced light, electron and correlative microscopy, together with expert support in bioimage analysis, segmentation, quantification and AI-assisted microscopy workflows.